Von
Hippel-Lindau syndrome is a genetic disorder characterized by formation of cysts and tumors in
different parts of the body. The symptoms associated with the disease depends
upon the location of tumor.
However,
gait disturbance, dizziness, weakness of the limbs, deafness, high blood
pressure, and vision problems are some common symptoms observed in the
patients. The available treatment options for the disease are surgical removal
of the tumor, high dose irradiation, and chemotherapies.
Request
to Get Free Sample Pages at:
Von
Hippel-Lindau syndrome is mostly found to be associated with pheochromocytoma.
The National Eye Institute (NEI), based in the U.S., is in the process of
developing a combination therapy of ranibizumab and E10030 for the treatment of
von Hippel-Lindau syndrome.
Make
Enquiry Before Buying the Report:
The report
provides a comprehensive understanding of the pipeline activities covering all
drug candidates under various stages of development, with the detailed analysis
of pipeline and clinical trials.
Pipeline analysis
of drugs by phases includes product description and development activities
including information about clinical results, designations, collaborations,
licensing, grants, technology, and others.
No comments:
Post a Comment